Cryo-Cell International, Inc.

CCEL

US2288951088

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
7.61 ^USD	-8.31%		-15.82%	+32.35%

04-15	Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	CI
04-15	Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	CI

Linda Kelley to Resign as Chief Scientific Officer from Cryo-Cell International, Inc, Effective May 16, 2014

May 15, 2014 at 05:04 pm

On May 2, 2014, Linda Kelley, Chief Scientific Officer, announced that she intended to resign from employment with the Cryo-Cell International, Inc. effective May 16, 2014.

Latest news about Cryo-Cell International, Inc.

Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	04-15	CI
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	04-15	CI
Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump	03-25	MT
Cryo-Cell to Explore Strategic Alternatives, Spin-Off Celle	03-24	CI
Cryo-Cell International, Inc. agreed to Spin-Off Celle Corp.	03-24	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	02-28	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2023	02-28	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-10-12	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-12	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-07-14	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-14	CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell 3000E Value Index	23-06-23	CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell Microcap Value Index	23-06-23	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-04-21	CI
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-21	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-02-28	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	23-02-28	CI
Insider Buy: Cryo Cell International	22-11-10	MT
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	22-10-18	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-18	CI
Cryo-Cell International, Inc. Primary Exchange Listing will Change to New York Stock Exchange from Nasdaq Capital Market	22-08-30	CI
Maxim Starts Cryo-Cell International at Buy With $12 Price Target	22-08-29	MT
Cryo-Cell International, Inc.(NYSEAM:CCEL) dropped from NASDAQ Composite Index	22-08-29	CI
Cryo-Cell International to Transfer Listing to NYSE American Stock Exchange	22-08-17	MT
Cryo-Cell International, Inc. Enters into A Credit Agreement with Susser Bank	22-07-22	CI

Chart Cryo-Cell International, Inc.

Duration

Period

More charts

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Sector

Healthcare Facilities & Services

Calendar

2024-07-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cryo-Cell International, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.61 USD

Average target price

9 USD

Spread / Average Target

+18.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CRYO-CELL INTERNATIONAL, INC.	+32.35%	61.68M
HCA HEALTHCARE, INC.	+18.69%	84.15B
CVS HEALTH CORPORATION	-25.20%	74.14B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.97%	26.92B
LABCORP HOLDINGS INC.	-10.46%	17.15B
FRESENIUS SE & CO. KGAA	-0.68%	16.83B
QUEST DIAGNOSTICS INCORPORATED	-0.73%	15.21B
NATERA, INC.	+72.88%	13.3B
TENET HEALTHCARE CORPORATION	+76.04%	12.99B
PURE HEALTH HOLDING	-25.79%	12.79B

Other Healthcare Facilities & Services

Cryo-Cell International, Inc.

Equities

CCEL

US2288951088

Healthcare Facilities & Services

Linda Kelley to Resign as Chief Scientific Officer from Cryo-Cell International, Inc, Effective May 16, 2014

Latest news about Cryo-Cell International, Inc.

Chart Cryo-Cell International, Inc.

Company Profile

Income Statement Evolution

Ratings for Cryo-Cell International, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services